Systemic chemotherapy for primary cutaneous b-cell lymphoma, leg-type: a case report

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Primary cutaneous lymphomas are a group of extranodal B-cell non-Hodgkin’s lymphomas. Primary cutaneous diffuse B-large cell lymphoma, leg-type, is an extremely rare and aggressive variant of primary cutaneous lymphoma. Due to the contradictory nature, poor prognosis, and high frequency of recurrence of this disease, the treatment of patients is multidisciplinary, based on an accurate histological and immunohistochemical classification as well as risk factor assessment. In this report, we present a clinical case of primary cutaneous B-large cell skin lymphoma, leg-type, with a positive response to chemotherapy.

Clinical case. A clinical observation of chemotherapy of a patient with primary B-large cell skin lymphoma, leg-type, is presented. The patient underwent 6 R-CHOP chemotherapy courses and achieved an uncertain complete disease remission.

Conclusion. The results obtained confirm the limited literature data on the need for timely administration of systemic chemotherapy in the management of this pathology.

Full Text

Restricted Access

About the authors

Inna A. Kamaeva

National Medical Research Centre for Oncology

Author for correspondence.
Email: inkamaeva@yandex.ru
ORCID iD: 0000-0003-3001-0675

младший научный сотрудник отдела лекарственного лечения опухолей

Russian Federation, Rostov-on-Don

Irina B. Lysenko

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

Nadezhda V. Nikolaeva

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

Elena A. Kapuza

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

Tatiana F. Pushkareva

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

Tatiana O. Lapteva

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

Alexey V. Velichko

National Medical Research Centre for Oncology

Email: inkamaeva@yandex.ru
Russian Federation, Rostov-on-Don

References

  1. Tadiotto Cicogna G, Ferranti M, Lazzarotto A, Alaibac M. Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas. Front Oncol. 2019;9:1238. doi: 10.3389/fonc.2019.01238
  2. Guskova NK, Selyutina ON, Novikova IA, et al. Morphological and immunofenotypic features of the monoclonal population of B-lymphocytes in chronic lymphocytic leukemia. South Russian Journal of Cancer. 2020;1(3):27-35. (In Russ). doi: 10.37748/2687-0533-2020-1-3-3
  3. Penskaya EA, Babaeva FE, Kravchenko SK, et al. Primary cutaneous diffuse b-large cell lymphoma, the leg type, with atypical clinical picture and indolent cours. Russian Journal Of Hematology And Transfusiology. 2015;60(4):41-44. (In Russ).
  4. Vitiello P, Sica A, Ronchi A, et al. Primary Cutaneous B-Cell Lymphomas: An Update. Front Oncol. 2020;10:651. doi: 10.3389/fonc.2020.00651
  5. Mitteldorf C, Berisha A, Pfaltz MC, et al. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am J Surg Pathol. 2017;41(7):998-1004. doi: 10.1097/PAS.0000000000000851
  6. Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol. 2011;65(5):991-1000. doi: 10.1016/j.jaad.2010.06.059
  7. Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535-541. doi: 10.1001/jamadermatol.2013.7452
  8. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671-3678. doi: 10.1182/blood-2004-04-1594
  9. Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133
  10. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150. doi: 10.1001/archderm.143.9.1144
  11. Ducharme O, Beylot-Barry M, Pham-Ledard A, et al. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. J Invest Dermatol. 2019;139(11):2334-2342 e2338. doi: 10.1016/j.jid.2019.05.008
  12. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926. doi: 10.1038/nm.3884
  13. Kuo H-P, Hsieh S, Schweighofer KJ, et al. The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 2015;126(23):699-699. doi: 10.1182/blood.V126.23.699.699
  14. Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847-853. doi: 10.1016/j.jaad.2005.01.093
  15. Arkhipova OE, Chernogubova EA, Tarasov VA, et al. The level of oncological diseases as an indicator of medical-ecological safety of territories (the rostov region being exemplified). Vestnik Yuzhnogo nauchnogo tsentra RAN. 2013;9(3):7-14. (In Russ).

Supplementary files

Supplementary Files
Action
1. Fig. 1. November 2019. Condition before the chemotherapy

Download (237KB)
2. Fig. 2. IHC staining, BCL2-positive, × 200

Download (217KB)
3. Fig. 3. IHC staining, CD45-positive, × 200

Download (299KB)
4. Fig. 4. IHC staining, Mum1-positive, × 200

Download (268KB)
5. Fig. 5. IHC staining, CD20-positive, × 200

Download (266KB)
6. Fig. 6. IHC staining, Ki67, × 200

Download (253KB)
7. Fig. 7. IHC staining, panCK-negative, × 200

Download (140KB)
8. Fig. 8. March 2020. Condition after 2 chemotherapy courses using R-CHOP algorithm

Download (115KB)
9. Fig. 9. April 2020. Condition after 3 chemotherapy courses using R-CHOP algorithm

Download (113KB)
10. Fig. 10. MRI, May 2020. Condition after 6 chemotherapy courses using R-CHOP algorithm

Download (65KB)
11. Fig. 11. March 2021

Download (238KB)

Copyright (c) 2020 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies